计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Lenalidomide (CC-5013)是Thalidomide的衍生物,是一种TNF-α分泌抑制剂,IC50为13 nM。 A Thalidomide analog known to have immunomodulatory properties
Information
Lenalidomide (CC-5013) is aTNF-αsecretion inhibitor withIC50of 13 nM in PBMCs. Lenalidomide (CC-5013) is a ligand ofubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 an
In vitro
Lenalidomide strongly induces IL-2 and sIL-2R production. Lenalidomide-induced tyrosine phosphorylation of CD28 on T cells is followed by a down-stream activation of NF-κB. Lenalidomide and pomalidomide inhibits autoubiquitination of CRBN in HEK293 T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA). Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplifies pomalidomide-mediated reductions in c-myc and IRF4 expression and increases in p21(WAF-1) expression. Long-term selection for Lenalidomide resistance in H929 myeloma cell lines is accompanied by a reduction in CRBN, while in DF15R myeloma cells resistant to both pomalidomide and Lenalidomide, CRBN protein is undetectable. Lenalidomide prevents induction of defects by down-regulating tumor cell inhibitory molecule expression. Lenalidomide prevents induction of tumor-induced T cell lytic synapse dysfunction. Lenalidomide treatment blocks CLL cell-induced T cell actin synapse dysfunction, mimicks antibody blockade, and down-regulates expression of CLL inhibitory ligands and their receptors on T cells. Lenalidomide treatment prevents tumor-induced immune suppression in FL, DLBCL, HL, MM, SCC, and OC and down-regulates immunosuppressive ligand expression on all tumor cells examined. CTL killing function significantly increases following antibody blockade of CLL inhibitory ligands or Lenalidomide treatment compared to control treatments. Treatment of autologous CLL-T cell co-cultures with Lenalidomide reverses impaired CD8+ T cell lytic synapse formation and granzyme B trafficking.
In vivo
The induction of angiogenesis by bFGF is significantly inhibited by oral treatment of Lenalidomide in a dose-dependent manner. Lenalidomide significantly decreases the percentage of vascularized area from 5.16% (control group) to 2.58% (50 mg/kg). Lenalidomide significantly reduces the calculated total MVL from 21.07 (control) to 8.11 (50 mg/kg). Lenalidomide significantly inhibites HUVEC migration through the fibronectin-coated membranes towards 0.1 ng/mL of bFGF at 100 μM, 1 ng/mL of VEGF at concentrations of 10 μM and 100 μM.
Cell Data
cell lines:
Concentrations:
Incubation Time:
Powder Purity:≥98%
| ALogP | -0.5 |
|---|
H301: 吞咽会中毒
H302: 吞食有害
H312: 皮肤接触有害
H332: 吸入有害
H360: 可能对生育能力或胎儿造成伤害
H372: 长期或反复接触会对器官造成损害
P260: 不要吸入灰尘/烟雾/气体/雾/蒸汽/喷雾。
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾
P264: 处理后要彻底洗手。
P270: 使用本产品时,请勿进食、饮水或吸烟。
P271: 仅在室外或通风良好的地方使用。
P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。
P321: 特殊处理(请参阅此标签上的...)。
P330: 漱口
P302+P352: 如皮肤沾染:用水充分清洗。
P304+P340: 如误吸入:将人转移到空气新鲜处,保持呼吸舒适体位。
P362+P364: 脱掉沾污的衣服,清洗后方可重新使用。
P405: 密闭存放
P501: 将内容物/容器送到批准的废物处理厂处理
P203: 使用前,获取、阅读并遵守所有安全说明。
P301+P316: 如果吞咽:立即寻求紧急医疗救助。
P301+P317: 如果被吞咽:请寻求医疗帮助。
P318: 如果暴露或担心,请就医。
P317: 寻求紧急医疗救助。
P319: 如果你感到不适,请寻求医疗帮助。
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | L408116 |